PSMA-IN-2, with the CAS number 2946600-14-0, is a small molecule inhibitor specifically designed to target the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. This compound is characterized by its ability to selectively bind to the PSMA enzyme, inhibiting its activity and thereby potentially impeding tumor growth and proliferation. PSMA-IN-2 is notable for its high affinity and specificity, making it a promising candidate for therapeutic applications in prostate cancer treatment. The compound's structure typically includes functional groups that enhance its binding properties and bioavailability. Additionally, PSMA-IN-2 may be utilized in imaging techniques, such as PET scans, to visualize PSMA-expressing tumors, aiding in diagnosis and treatment planning. Its development reflects ongoing research efforts to create targeted therapies that minimize side effects associated with conventional cancer treatments. Overall, PSMA-IN-2 represents a significant advancement in the field of oncological pharmacology, particularly for patients with advanced prostate cancer.

PSMA-IN-2

2946600-14-0: PSMA-IN-2, with the CAS number 2946600-14-0, is a small molecule inhibitor specifically designed to target the prostate-specific membrane antigen (PSMA), which is overexpressed in prostate cancer cells. This compound is characterized by its ability to selectively bind to the PSMA enzyme, inhibiting its activity and thereby potentially impeding tumor growth and proliferation. PSMA-IN-2 is notable for its high affinity and specificity, making it a promising candidate for therapeutic applications in prostate cancer treatment. The compound's structure typically includes functional groups that enhance its binding properties and bioavailability. Additionally, PSMA-IN-2 may be utilized in imaging techniques, such as PET scans, to visualize PSMA-expressing tumors, aiding in diagnosis and treatment planning. Its development reflects ongoing research efforts to create targeted therapies that minimize side effects associated with conventional cancer treatments. Overall, PSMA-IN-2 represents a significant advancement in the field of oncological pharmacology, particularly for patients with advanced prostate cancer.

<p>PSMA-IN-2, an inhibitor of PSMA with a K i value of 1.07 nM, exhibits favorable in vivo NIR imaging (λ EM = 1088 nm, λ ex = 808 nm) and is useful for NIRII image-guided tumor resection surgery in PSMA-positive tumor-bearing mice [1].</p>

CAS 2946600-14-0

PSMA-IN-2

PSMA-IN-2

Ref: TM-T87271